Ampion is the company's lead biologic for the chronic treatment (repeat injections) of pain in osteoarthritis of the knee. DA-DKP, the active ingredient in Ampion, is a derivative of one of the most common proteins in our blood namely Human Serum Albumin. Having obtained the clinical path guidance for Ampion for chronic osteoarthritis of the knee from the FDA, the company expects to start enrollment in two phase III trials this quarter. (3Q12). Ampion has been issued composition of matter, synthetic, method of uses and manufacturing patents worldwide. It is estimated that there are more than 20 million osteoarthritis patients in the US, of which 10 million of them have osteoarthritis of the knee. The only effective treatment for osteoarthritis if pain becomes debilitating is joint replacement. The fact that oral analgesics, hyaluronic acids and large molecule single-target biologics are largely ineffective or only show modest efficacy offers Ampion, whose active ingredient has nonsteroidal, anti-inflammatory and analgesic properties, a good opportunity, says the company. Earlier in the week, the company announced that it is advancing NCE001, from its proprietary methylphenidate derivatives family of compounds, to preclinical development for the treatment of glioblastoma multiforme, renal cell carcinoma and inflammatory breast cancer.